Avivagen Inc.

06/11/2021 | Press release | Distributed by Public on 06/12/2021 06:52

Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

Ottawa, ON / Business Wire/ June 11, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ('Avivagen'), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of June 30, 2021, which has been extended to January 28, 2022.